7 results about "Protopanaxatriol" patented technology

The application belongs to the technical field of genetic engineering, and discloses a kind of saccharomyces cerevisiae for producing rare ginsenoside by seaweed biomass and a construction method and application thereof.The saccharomyces cerevisiae has the following characteristics: overexpression of agarase, neojuncanohydrolase, hydroxymethylglutaryl coenzyme A reductase, isopentenyl diphosphate delta isomerase, dammaradienol synthase, protopanaxadiol synthase, cytochrome P450 reductase, protopanaxatriol synthase and glycosyltransferase.The application combines enzymolysis of seaweed biomass with fermentation of rare ginsenoside, which not only endows wild-type yeast with the ability to degrade seaweed biomass that it originally does not have, but also effectively improves the yield of squalene and downstream terpenes (rare ginsenoside Rh1) by overexpression of tHMG1 and IDI1.The saccharomyces cerevisiae can effectively utilize seaweed biomass to obtain squalene and rare ginsenoside Rh1, and has the characteristics of simplicity, economy and ecological friendliness, can convert cheap biomass into high-value products, and provides a way for the development of marine bioeconomy.

The invention provides an application of ginseng oil body in preparation of a medicine for preventing and / or treating colitis, and belongs to the technical field of ginseng seed oil. The detection shows that the oil core structure of the ginseng oil body mainly consists of oleic acid and linoleic acid, and is different from the triglyceride core of the oil body obtained from the existing oil crops. Through lipidomics detection and analysis, the phospholipid monomolecular layer has 335 phospholipids (positive ion mode) and 269 phospholipids (negative ion mode). Through proteomics detection and analysis, 24 kinds of Panax proteins are identified. The condition that the oil core of the ginseng oil body contains protopanaxatriol (PPT) is identified through high performance liquid chromatography-high resolution mass spectrometry. In-vitro detection shows that the ginseng oil body has anti-inflammatory and anti-oxidation effects.

The invention is suitable for the technical field of biological medicine, and provides application of 20 (S)-protopanaxatriol in preparation of a medicine for inhibiting tumor metastasis of liver cancer chemotherapy. According to the embodiment of the invention, a molecular mechanism of chemotherapy-induced liver cancer immunosuppression and metastasis increase is analyzed and studied, a key effect of an SHP2-PI3K / AKT signal axis in TAM M2 polarization is disclosed, a novel natural small molecule 20 (S)-protopanaxatriol capable of inhibiting the activity of SHP2 is provided, TAM is blocked from being polarized to an M2 type by inhibiting phosphorylation of SHP2 and activation of a downstream PI3K / AKT signal channel, and the activity of SHP2 is inhibited. Therefore, the tumor immune microenvironment after chemotherapy is improved, the tumor metastasis risk after chemotherapy is reduced, and the overall treatment effect is improved on the premise that safety is guaranteed.

The present application relates to the field of medicine, in particular to a nano delivery system of protopanaxatriol targeting Twist1-Ku70-Sirt1 complex and application of the nano delivery system in treatment of colon inflammation related colorectal cancer, the nano delivery system comprising: (a) protopanaxatriol nanocrystal; (b) lipoic acid modified chitosan; and (c) crosslinking agent; wherein the average particle size of the protopanaxatriol nanocrystal is 100-200 nm; the modification degree of the lipoic acid modified chitosan is 15-25%; the crosslinking agent is sodium tripolyphosphate; and the average particle size of the nano delivery system is 300-500 nm, the solubility and bioavailability of protopanaxatriol are significantly improved by preparing protopanaxatriol into nanocrystal.

The invention discloses a novel oil-soluble micelle preparation. The component A comprises lecithin, soya bean lecithin, egg yolk lecithin, 1-palmitoyl-2-oleoyl lecithin, phosphatidylserine, phosphatidylinositol, phosphatidyl glycerol, cardiolipin, cephalin and dipalmitoyl phosphatidylcholine, and the component B comprises lecithin, soya bean lecithin, egg yolk lecithin, 1-palmitoyl-2-oleoyl lecithin, phosphatidylserine, phosphatidylinositol, phosphatidyl glycerol, phosphatidylcholine, cephalin and dipalmitoyl phosphatidylcholine; one or more of dipalmitoyl phosphatidyl ethanolamine and dipalmitoyl phosphatidyl ethanolamine; the component B comprises a component B1 and a component B2, and the component B1 comprises one or more of phytosterol, cholesterol, ergosterol, protopanoxadiol, protopanaxatriol, ganoderic acid, phytol, isophytol, retinol, andrographolide, paclitaxel, artemisinin and bisabolol; and the component B2 is prepared from one or more of 1, 2-hexanediol, ethylhexylglycerin, cyclohexyl glycerin, absolute ethyl alcohol and isosorbide dimethyl ether. The key point of the invention is to provide a low-cost formula and a low-cost preparation method for preparing the oil-soluble micelle preparation.

The invention is applicable to the technical field of biological medicines, and provides application of 20 (S)-protopanaxatriol in preparation of a medicine for reversing chemotherapy resistance of liver cancer. The invention provides application of 20 (S)-protopanaxatriol (20 (S)-protopanaxatriol, hereinafter referred to as 20S-PPT) which is derived from ginseng in preparation of drugs for reversing chemotherapy resistance of liver cancer, the sensitivity of liver cancer cells to chemotherapy drugs is improved, the chemotherapy-induced apoptosis effect is enhanced, and the in-vivo anti-tumor effect is improved on the premise that safety is guaranteed.

The present application belongs to the technical field of medicine and pharmacy, and in particular relates to an application of proto-prosolan in preparation of a Streptococcus suis type 2 capsule inhibitor. The present application discloses that proto-prosolan can significantly weaken the pathogenicity and immune escape ability of Streptococcus suis type 2 by inhibiting capsule synthesis, and then effectively plays an anti-infection role. Compared with vaccines, antibodies and phage enzymes and other highly limited anti-capsule strategies specific to serotypes, proto-prosolan, as an anti-toxicity inhibitor of Streptococcus suis type 2, has potential advantages such as broad spectrum, and has important scientific significance and application value for the research and development of new anti-drugs in the future. The proto-prosolan can be applied to the preparation of a Streptococcus suis type 2 capsule inhibitor and a drug for preventing and treating Streptococcus suis type 2 infection.